In the past week, LRMR stock has gone up by 8.53%, with a monthly decline of -10.42% and a quarterly plunge of -49.76%. The volatility ratio for the week is 10.75%, and the volatility levels for the last 30 days are 7.68% for Larimar Therapeutics Inc The simple moving average for the past 20 days is -0.25% for LRMR’s stock, with a -52.02% simple moving average for the past 200 days.
Is It Worth Investing in Larimar Therapeutics Inc (NASDAQ: LRMR) Right Now?
Additionally, the 36-month beta value for LRMR is 0.80. There are mixed opinions on the stock, with 10 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for LRMR is 36.46M and currently, short sellers hold a 14.74% ratio of that float. The average trading volume of LRMR on March 06, 2025 was 745.85K shares.
LRMR) stock’s latest price update
Larimar Therapeutics Inc (NASDAQ: LRMR)’s stock price has gone rise by 13.98 in comparison to its previous close of 2.79, however, the company has experienced a 8.53% increase in its stock price over the last five trading days. globenewswire.com reported 2025-03-03 that BALA CYNWYD, Pa., March 03, 2025 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will present and participate in 1×1 investor meetings at the Leerink Partners Global Healthcare Conference, taking place in Miami Beach, FL from March 10 – 12, 2025.
Analysts’ Opinion of LRMR
Many brokerage firms have already submitted their reports for LRMR stocks, with Truist repeating the rating for LRMR by listing it as a “Buy.” The predicted price for LRMR in the upcoming period, according to Truist is $18 based on the research report published on January 29, 2025 of the current year 2025.
Oppenheimer, on the other hand, stated in their research note that they expect to see LRMR reach a price target of $26. The rating they have provided for LRMR stocks is “Outperform” according to the report published on October 16th, 2024.
Wedbush gave a rating of “Outperform” to LRMR, setting the target price at $22 in the report published on October 03rd of the previous year.
LRMR Trading at -9.31% from the 50-Day Moving Average
After a stumble in the market that brought LRMR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.43% of loss for the given period.
Volatility was left at 7.68%, however, over the last 30 days, the volatility rate increased by 10.75%, as shares sank -13.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.56% lower at present.
During the last 5 trading sessions, LRMR rose by +8.53%, which changed the moving average for the period of 200-days by -59.59% in comparison to the 20-day moving average, which settled at $3.19. In addition, Larimar Therapeutics Inc saw -17.83% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for LRMR
The total capital return value is set at -0.36. Equity return is now at value -44.50, with -40.11 for asset returns.
Based on Larimar Therapeutics Inc (LRMR), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -10.87.
Currently, EBITDA for the company is -41.45 million with net debt to EBITDA at 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.10.
Conclusion
In conclusion, Larimar Therapeutics Inc (LRMR) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
